GSK announces results from interim analysis of the DREAMM-7 phase III trial
On 6 February 2024, GlaxoSmithKline (GSK) announced results from an interim analysis of the DREAMM-7 phase III trial presented at an American Society of Clinical Oncology (ASCO) online plenary session. The trial is evaluating belantamab mafodotin (“belamaf” or trade name Blenrep®) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second line and later treatment of relapsed or refractory myeloma. Key results from the presentation include: A main research question in…
Details